发现了具有针对乳腺癌增强选择性的C-9化柏柏林衍生物
Ying-Hao Liao1, Yu-Jiao Wang1, Jin-Qi Wang1
1School of Chemistry and Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, China.
Bioorganic & medicinal chemistry letters
|February 26, 2026
概括
新的柏柏林衍生物对乳腺癌细胞具有更好的选择性. 一些化合物表现出强烈的抗癌活性和有利的药理动力学特征,表明它们可能成为新型治疗药物.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症药理学 癌症药理学
背景情况:
- 柏柏林是一种天然产品,已显示出抗癌性质,但缺乏选择性.
- 分子杂交是一种提高药物疗效和点特异性的策略.
- 开发选择性抗癌药物至关重要,以尽量减少副作用.
研究的目的:
- 设计和合成具有提高乳腺癌选择性的新柏林衍生物.
- 评估这些衍生物的体外抗增殖活性和选择性.
- 评估药物动力学特性和潜在的作用机制.
主要方法:
- 通过分子杂交合成合成十八种柏柏林衍生物,结合酸/基组.
- 针对人类乳腺癌细胞系 (MDA-MB-468,MCF-7) 和正常HEK-293细胞的体外抗增殖试验.
- 计算ADME分析和分子对接研究.
主要成果:
- 一些衍生品,包括4c,5d,5f和8b,显示出显著的抗扩散活性和高选择性指数.
- 化合物8b和5f被确定为潜在的口服药物候选物,而4c显示出血脑屏障的透性.
- 分子对接建议蛋白酶体抑制作为化合物8b的一种机制.
结论:
- 合成的柏柏林衍生物显示出有前途的抗癌活性和对乳腺癌的选择性.
- 特定化合物表现出有利的类似药物的特性和潜在的治疗应用.
- 对蛋白质酶抑制机制的进一步研究是有必要的.
更多相关视频
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
29.9K
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.7K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
